Citation Impact
Citing Papers
The Pervasive Presence of Fluctuating Oxygenation in Tumors
2008
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Concordant Regulation of Gene Expression by Hypoxia and 2-Oxoglutarate-dependent Dioxygenase Inhibition
2006 StandoutNobel
Hallmarks of Cancer: The Next Generation
2011 Standout
Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
2001
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
Physiologic Mechanisms of Therapeutic Resistance: Blood Flow and Hypoxia
1995
Actions and interactions of nitric oxide, carbon monoxide and hydrogen sulphide in the cardiovascular system and in inflammation — a tale of three gases!
2009
Applicability of animal tumor data to cancer therapy in humans
1988
A view on drug resistance in cancer
2019 StandoutNature
Photodynamic Therapy
1998 Standout
Targeting HIF-1 for cancer therapy
2003 StandoutNobel
Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation
2000
Novel Imaging Provides New Insights into Mechanisms of Oxygen Transport in Tumors
2009
Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapy
1996
Drug penetration in solid tumours
2006 Standout
Proliferation and hypoxia in human squamous cell carcinoma of the cervix: First report of combined immunohistochemical assays
1997
Cancer Metastasis: Building a Framework
2006 Standout
Imaging in the era of molecular oncology
2008 StandoutNature
Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy
1995
Tumor angiogenesis: past, present and the near future
2000
HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
2013 StandoutNobel
PRECLINICAL EXAMINATION OF FIRST and SECOND GENERATION PHOTOSENSITIZERS USED IN PHOTODYNAMIC THERAPY
1991
New insights into nNOS regulation of vascular homeostasis
2005 StandoutNobel
Temporal changes in pO2 of R3230Ac tumors in fischer-344 rats
1998
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Angiogenesis in cancer and other diseases
2000 StandoutNature
Tumor Hypoxia and Malignant Progression
2004
Biological Functions of Autophagy Genes: A Disease Perspective
2019 Standout
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
2015 Standout
Assessing responses to cancer therapy using molecular imaging
2006
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF
2003
Differential Sensitivity of Hypoxia Inducible Factor Hydroxylation Sites to Hypoxia and Hydroxylase Inhibitors
2011 StandoutNobel
Photofrin ®, but not benzoporphyrin derivative, stimulates hematopoiesis in the mouse
1993
Selection and Analysis of a Mutant Cell Line Defective in the Hypoxia-inducible Factor-1 α-Subunit (HIF-1α)
1998 StandoutNobel
Regulation of Ferroptotic Cancer Cell Death by GPX4
2014 Standout
Tirapazamine causes vascular dysfunction in HCT-116 tumour xenografts
2006
Regulation of angiogenesis by hypoxia: role of the HIF system
2003 StandoutNobel
Hypoxia Inhibits G1/S Transition through Regulation of p27 Expression
2001 StandoutNobel
Aspirin Inhibits mTOR Signaling, Activates AMP-Activated Protein Kinase, and Induces Autophagy in Colorectal Cancer Cells
2012
Macrophage Responses to Hypoxia
2005
Clinical Applications of Research on Angiogenesis
1995 Standout
Immunity, Inflammation, and Cancer
2010 Standout
The biology of the combretastatins as tumour vascular targeting agents
2002
Keynote address: The influence of microenvironmental factors on the activity of radiation and drugs
1991
Arginase Activity is Inhibited by l -NAME, both In Vitro and In Vivo
2002
Cellular levels of photosensitisers in tumours: the role of proximity to the blood supply
1994
Vascular‐targeting therapies for treatment of malignant disease
2004
Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. II. RSU 1069
1995
Targeting gene expression to hypoxic tumor cells
1997 StandoutNobel
High-Resolution Microtubule Structures Reveal the Structural Transitions in αβ-Tubulin upon GTP Hydrolysis
2014 StandoutNobel
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Factors that influence the penetration of methotrexate through solid tissue
2000
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11
2003
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
2012
Intermittent blood flow in the KHT sarcoma--flow cytometry studies using Hoechst 33342
1990
Distribution of Photofrin between tumour cells and tumour associated macrophages
1991
Low density lipoprotein receptor pathway in the delivery of Photofrin: How much is it relevant for selective accumulation of the photosensitizer in tumors?
1992
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
2001 Standout
Significant correlation of hypoxia-inducible factor-1α with treatment outcome in cervical cancer treated with radical radiotherapy
2003
Oxygen Sensing, Homeostasis, and Disease
2011 StandoutNobel
Multilayers of Cells Growing on a Permeable Support:An in Vitro Tumour Model
1997
Factors and Mechanism of “EPR” Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS
2005
Cancer-related inflammation
2008 StandoutNature
Slow penetration of anthracyclines into spheroids and tumors: a therapeutic advantage?
1990
ENHANCED MACROPHAGE CYTOTOXICITY AGAINST TUMOR CELLS TREATED WITH PHOTODYNAMIC THERAPY
1994
Angiogenesis as a therapeutic target
2005 StandoutNature
Up-regulation of Apoptosis Inhibitory Protein IAP-2 by Hypoxia
2001 StandoutNobel
Radical causes of cancer
2003
Correlation of Subcellular and Intratumoral Photosensitizer Localization with Ultrastructural Features After Photodynamic Therapy
1996
A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome
2009
Photoswitchable anticancer activity via trans–cis isomerization of a combretastatin A-4 analog
2015
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
2012
Synthesis, Characterization, and Bioactivity of the Photoisomerizable Tubulin Polymerization Inhibitor azo-Combretastatin A4
2015
Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
1993
Vascular Targeting Agents as Cancer Therapeutics
2004
The OxyLite: a fibre-optic oxygen sensor.
1999
Comparison of tumor and normal tissue oxygen tension measurements using OxyLite or microelectrodes in rodents
2001
Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
2011 StandoutNobel
Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
1998 StandoutScience
Regulation of Protein Synthesis by Hypoxia via Activation of the Endoplasmic Reticulum Kinase PERK and Phosphorylation of the Translation Initiation Factor eIF2α
2002
Drug Delivery Systems: Entering the Mainstream
2004 StandoutScience
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.
2002
Multistage nanoparticle delivery system for deep penetration into tumor tissue
2011 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors
1998
G 1 Events and Regulation of Cell Proliferation
1989 StandoutScience
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression
2012 StandoutNobel
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Acid pH in tumors and its potential for therapeutic exploitation.
1989
Emerging Targets in Photopharmacology
2016 StandoutNobel
Metal–Organic Frameworks in Biomedicine
2011 Standout
Tumor hypoxia: its impact on cancer therapy
1987
The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.
1999
HIF-1 and human disease: one highly involved factor
2000 StandoutNobel
The tumor vascular targeting agent combretastatin A–4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells
2002
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Combining TRAIL with PI3 Kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling
2013
Genes Expressed in Human Tumor Endothelium
2000 StandoutScience
Penetration of anticancer drugs through solid tissue: a factor that limits the effectiveness of chemotherapy for solid tumors.
1999
Intermittent blood flow in a murine tumor: radiobiological effects.
1987
Works of D J Chaplin being referenced
Guidelines for the welfare and use of animals in cancer research
2010 Standout
Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts
1999
Proportion of infiltrating IgG-binding immune cells predict for tumour hypoxia
2001
The Effect of Vinca Alkaloids on Tumour Blood Flow
1994
Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours
1995
The Effect of Therapy on Tumour Vascular Function
1991
Possible Mechanisms for Intermittent Blood Flow in the Murine SCCVII Carcinoma
1991
Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents.
1996
Measurement of Tumor Oxygenation: A Comparison between Polarographic Needle Electrodes and a Time-Resolved Luminescence-Based Optical Sensor
1997
Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.
2001
Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug.
1998
Photofrin uptake by murine macrophages.
1991
Effect of Nicotinamide on the Microregional Heterogeneity of Oxygen Delivery Within a Murine Tumor
1990
Oxygen and nitroreductase-dependent binding of af-2 in spheroids and murine tumors
1986
Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours
1985
Cell selection from a murine tumour using the fluorescent probe Hoechst 33342
1985
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
1997
Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes.
1996
Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine.
1997